Literature DB >> 32458242

Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis.

Adem Kucuk1, Medine Cumhur Cure2, Erkan Cure3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32458242      PMCID: PMC7249985          DOI: 10.1007/s10067-020-05178-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


× No keyword cloud information.
Dear Sir, Myalgia is a common symptom in patients with viral infections such as novel coronavirus disease 2019 (COVID-19) and influenza. Myalgia reflects generalized inflammation and cytokine response and can be the onset symptom of 36% of patients with COVID-19 [1]. Back pain in COVID-19 may usually indicate pneumonia. Why is the common myalgia caused by COVID-19 longer and more severe than myalgia of other viral infections? Myalgia and fatigue in patients with COVID-19 may be longer in duration than other viral infections and may be unresponsive to conventional painkillers. According to our observation, when viral load is reduced with virus treatment, muscle pain may decrease. In addition to the classic mechanisms of myalgia known in viral infections, COVID-19 can cause musculoskeletal pain with completely different mechanisms. COVID-19 enters the cell by penetrating ACE2 at low cytosolic pH and causes infection in the pulmonary system [2, 3]. The presence of ACE2 has also been demonstrated in the brain, kidney, vascular smooth muscle, and skeletal muscles [4, 5]. A recent article reported that lactate levels increased due to surplus cell damage during COVID-19 infection [6]. In hyperlactatemia, the oxygen-carrying capacity of erythrocytes to the tissues is impaired and the tissues remain hypoxic. The virus can spread through the bloodstream or vascular endothelium and cause infection in all tissues containing ACE2 such as the heart and brain. Therefore, the musculoskeletal system can also undergo infection. Increasing creatinine kinase levels during COVID-19 infection proves muscle involvement. When muscle tissue cannot provide the necessary energy in aerobic ways during exercise, lactate begins to accumulate in the muscles. Monocarboxylate transporter (MCT) (synonym, lactate/H+ ion symporter) is activated to prevent lactate accumulation [7]. MCT pumps lactate and H+ ion simultaneously from the extracellular space to the intracellular space and from the intracellular space to the mitochondria. In anaerobic conditions, lactate dehydrogenase (LDH) increases lactate formation from pyruvate [7, 8]. Under normal conditions, MCTs increase between 32 and 76% during exercise [7, 8]. During intensive exercise, MCT capacities may increase up to 3–4 times as maximum [7]. Due to exceeding the capacity of MCTs and other regulatory pumps, lactate and H+ ion accumulation occur in the cytosol, and the cytosol pH decreases [8]. ATP synthesis is reduced due to anaerobic glycolysis. Decreased ATP synthesis and low intracellular pH cause pain and fatigue [7, 9]. In hyperlactatemia, the oxygen-carrying capacity of erythrocytes and the transport of oxygen to the tissues are highly reduced. As if exercising intensely, the musculoskeletal system may remain deoxygenated and muscles may take place ischemic during COVID-19 infection. Therefore, pain may occur in the muscle tissues remaining ischemic with a mechanism similar to sickle cell disease. Also, during the hypoxic ischemia, the increase of growth factors, cytokines levels, ischemic conditions, and microvascular changes can trigger pain by overexpression in the dorsal root ganglion [10]. In conclusion, LDH increases when the virus damages muscles and other tissues. Due to both increased LDH and anaerobic glycolysis, lactate level may increase excessively. Cytosolic pH may decrease more. Muscle pain may increase further due to increased lactate levels, low pH, and low oxygen levels. It is necessary to eliminate the cause of hypoxia for treatment in this pain type. Painkillers may not be effective. When the virus load decreases, the oxygenation of erythrocytes increases, and muscle lactate level decreases. Pain can disappear with virus treatment.
  20 in total

Review 1.  COVID-19 and Liver Damage: Narrative Review and Proposed Clinical Protocol for Critically ill Pediatric Patients.

Authors:  Michele Luglio; Uenis Tannuri; Werther Brunow de Carvalho; Karina Lucio de Medeiros Bastos; Isadora Souza Rodriguez; Cintia Johnston; Artur Figueiredo Delgado
Journal:  Clinics (Sao Paulo)       Date:  2020-11-11       Impact factor: 2.365

Review 2.  The Neurological Complexities and Prognosis of COVID-19.

Authors:  Inderbir Padda; Nimrat Khehra; Urooj Jaferi; Mayur S Parmar
Journal:  SN Compr Clin Med       Date:  2020-09-29

Review 3.  Role of Melatonin on Virus-Induced Neuropathogenesis-A Concomitant Therapeutic Strategy to Understand SARS-CoV-2 Infection.

Authors:  Prapimpun Wongchitrat; Mayuri Shukla; Ramaswamy Sharma; Piyarat Govitrapong; Russel J Reiter
Journal:  Antioxidants (Basel)       Date:  2021-01-02

Review 4.  Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity.

Authors:  Deepmala Karmakar; Basudev Lahiri; Piyush Ranjan; Jyotirmoy Chatterjee; Pooja Lahiri; Sanghamitra Sengupta
Journal:  Pathogens       Date:  2020-12-23

5.  Pathophysiological Mechanisms and Neurological Manifestations in COVID-19.

Authors:  Kapil Gangadhar Zirpe; Subhal Dixit; Atul Prabhakar Kulkarni; Harsh Sapra; Gaurav Kakkar; Rahul Gupta; Atma Ram Bansal; Arun Garg; Santosh Kumar Dash; Anil Gurnani; Azizullah Khan; Khalid Ismail Khatib; Pandurang Reddy Mare
Journal:  Indian J Crit Care Med       Date:  2020-10

Review 6.  Severe Acute Respiratory Syndrome Coronavirus 2-Induced Neurological Complications.

Authors:  Shijia Yu; Mingjun Yu
Journal:  Front Cell Dev Biol       Date:  2020-12-10

7.  Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis.

Authors:  Adonis Sfera; Carolina Osorio; Carlos M Zapata Martín Del Campo; Shaniah Pereida; Steve Maurer; Jose Campo Maldonado; Zisis Kozlakidis
Journal:  Front Cell Neurosci       Date:  2021-06-25       Impact factor: 5.505

Review 8.  COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.

Authors:  Md Farhad Hossain; Sharifa Hasana; Abdullah Al Mamun; Md Sahab Uddin; Mir Imam Ibne Wahed; Sabarni Sarker; Tapan Behl; Irfan Ullah; Yesmin Begum; Israt Jahan Bulbul; Md Shah Amran; Md Habibur Rahman; May N Bin-Jumah; Saad Alkahtani; Shaker A Mousa; Lotfi Aleya; Mohamed M Abdel-Daim
Journal:  Front Pharmacol       Date:  2020-10-16       Impact factor: 5.810

9.  Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection.

Authors:  Erkan Cure; Medine Cumhur Cure
Journal:  Med Hypotheses       Date:  2020-08-14       Impact factor: 1.538

Review 10.  Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.

Authors:  Saikat Dewanjee; Jayalakshmi Vallamkondu; Rajkumar Singh Kalra; Nagaprasad Puvvada; Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2021-06-24       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.